

Sam Manger

On Behalf of PRaVDA




Aim of Talk




- Introduce proton therapy
- Introduce proton computed tomography (pCT)
- The need for pCT
- PRaVDA and the story so far
- My own work developing a phantom for use with PRaVDA

Proton Therapy


- Type of radiotherapy using protons
- Energy loss of protons described by Bethe-Bloch formula
- Leads to characteristic Bragg peak, where range is determined by beam energy
- Lots of dose deposited at target, minimal entry dose, no exit dose
- In theory, lower integral dose to patient
- Beam of 230 MeV has range of around 41 cm in water






Limitations of Proton Therapy

- Uncertainty in the delivered proton range in-vivo is ~ 3%
- Biggest source is from conversion of x-ray HU to proton stopping powers
- Stopping powers are calculated using tabulated I-values, which are also subject to uncertainty





OP PUBLISHING

PHYSICS IN MEDICINE AND BIOLOGY

Phys. Med. Biol. 57 (2012) R99-R117

doi:10.1088/0031-9155/57/11/R99

TOPICAL REVIEW

Range uncertainties in proton therapy and the role of Monte Carlo simulations


Harald Paganetti

Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

Source of range uncertainty in the patient	Range uncertainty without Monte Carlo	Range uncertainty with Monte Carlo
Independent of dose calculation		
Measurement uncertainty in water for commissioning	$\pm 0.3 \text{ mm}$	$\pm 0.3 \text{ mm}$
Compensator design	$\pm 0.2 \text{ mm}$	$\pm 0.2 \text{ mm}$
Beam reproducibility	$\pm 0.2 \text{ mm}$	$\pm 0.2 \text{ mm}$
Patient setup	$\pm 0.7 \text{ mm}$	$\pm 0.7 \text{ mm}$
Dose calculation		
Biology (always positive) ^	$+\sim 0.8\%$	$+\sim 0.8\%$
CT imaging and calibration	$\pm 0.5\%^{a}$	$\pm 0.5\%^{a}$
CT conversion to tissue (excluding I-values)	±0.5% ^b	$\pm 0.2\%^{g}$
CT grid size	±0.3% ^c	±0.3% ^c
Mean excitation energy (I-values) in tissues	± 1.5% ^d	±1.5% ^d
Range degradation; complex inhomogeneities	-0.7% ^e	$\pm 0.1\%$
Range degradation; local lateral inhomogeneities *	$\pm 2.5\%^{f}$	$\pm 0.1\%$
Total (excluding *, ^)	2.7% + 1.2 mm	2.4% + 1.2 mm
Total (excluding ^)	4.6% + 1.2 mm	2.4% + 1.2 mm

A solution - Proton CT

- Proton CT directly measures stopping power in-vivo
- Trackers count each proton entering an exiting the patient
- "Range Telescope" (or RERD) measures residual energy
- Require 200 protons per voxel per projection
- ► 10⁶ protons per projection for 10 cm³ area



Schematic of ideal proton-tracking proton CT system

Redrawn from G Poludniowski, N M Allinson, and P M Evans The British Journal of Radiology 2015 88:1053

Who are PRaVDA?



- PRaVDA Proton RAdiotherapy Verification and Dosimetry Applications
- ► Team of researchers from 12 institutions and 2 industrial partners aiming to build the world's first solid-state proton CT device
- Supported by Wellcome Trust Translation Award Scheme, Grant 098285

































PRaVDA Technology – Strip Trackers


- Developed by University of Liverpool HEP group
- Manufactured by Micron Semiconductor
- Used to calculate input and output vectors of protons entering and exiting phantom
- 26 MHz readout cycle, triggered from cyclotron beam clock
 - ☐ Active area of 93x96 mm²
 - ☐ 150 um thick n-in-p silicon
 - ☐ Strip pitch of 90.8 um
 - ☐ Strip length of 48 mm
 - □ 2048 strips, 1024 read out from each side
 - ☐ 16 ASICs (8 for each strip half)
 - Double threshold binary readout




x-u-v Orientation

- Each tracking unit consists of 3 strip sensors, rotated at 60 degrees to each other
- The x-u-v orientation reduces ambiguities and allows for higher occupancies in the trackers
- Published Patent WO2015/189601

















PRaVDA Technology – Range Telescope

- Range telescope uses silicon strips interleaved with Perspex absorbers to measure residual range of protons
- Proton track length in RT is the matched with hits in trackers to allow backprojection and image reconstruction



iThemba LABS November 2016

- No suitable test beams in the UK (yet)
- We were hosted by iThemba LABS, South Africa
- Cyclotron providing 192 MeV clinical proton beam
- Performed calibration of instrument and took several pCT scans
- 2 weekends of testing, 72 hour shifts
- Returned with ~10 Tb of data!



Installation in SA



Proximal trackers

Distal trackers


Range telescope

Compensator

Phantom







Imaging Objects



Perspex Phantom High energy pCT (191 MeV) Low energy pCT (125 MeV)




Film Phantom
High energy pCT (191 MeV)
Low energy pCT (125 MeV)
Treatment dose to film




Tissue/"Meat" Phantom Low energy pCT (125 MeV)

Film Phantom


- Designed and evaluated for use using GATE, a Geant4-based simulation framework
- Designed to be imaged with x-ray CT and proton CT
- Also "treated" with a proton beam
- Monte Carlo simulation to be performed on results from pCT and xCT images to evaluate stopping power measurements and compare to "real" experiment













- First reconstruction completed, using 2m protons per angle
- A few streaky artefacts originating from the "lung" insert
- Air gap around the film insert is less visible this is good as should be negligible

PRELIMINARY RESULTS





- Line profile through inserts shows good reconstruction of stopping powers through polyethylene body and "bone" insert
- "Lung" insert reconstruction is below expected value under investigation

Future work (myself)

- Import voxelised geometries from xCT and pCT into simulation to perform Monte Carlo dose delivery
- Repeat experiment in silico with virtual anatomical phantom using validated pCT and xCT simulations

Future work (PRaVDA)

- Produce a spot-scanning proton CT scan
- Complete analysis of existing data from iThemba
 - Still a lot to make sense of and finalize!

Acknowledgements

University of Lincoln

Nigel Allinson Grainne Riley Chris Waltham Michela Esposito

University of Birmingham

Phil Allport David Parker Tony Price Ben Phoenix

University of Liverpool

Jon Taylor Gianluigi Casse Tony Smith Ilya Tsurin

University of Surrey

Phil Evans Nikos Liakos **University of Warwick**

Sam Manger Jon Duffy

Karolinska University Hospital, Sweden Gavin Poludniowski

University Hospital Birmingham NHS Foundation Trust

Stuart Green

University Hospital Coventry and Warwickshire NHS Trust

Spyros Manolopoulos

iThemba LABS, South Africa

Jaime Nieto-Camero Julyan Symons ISDI

Thalis Anaxagoras Andre Fant Przemyslaw Gasiorek Michael Koeberle

aSpect

Marcus Verhoeven Daniel Welzig Daniel Schöne Frank Lauba






Questions?

Patient Benefits

- Finite range of proton beam promises lower integral dose delivered to patient
- Reduce damage to healthy tissues
- Particularly important for paediatric cancers
- Reduces late effects, second cancers
- Better quality of life



Dose distributions for a) 3-dimensional proton beam treatment and b) intensity-modulated x-ray radiotherapy. Target volume shown in purple. Proton beam plans demonstrate superior sparing of normal structures.

Jimenez, R. B. et al. *International Journal of Radiation Oncology Biology Physics*, 87(1), 120–126.


X-ray HU to SP Conversion

- X-ray CT scanner uses Hounsfield Units
- Hounsfield Units measure x-ray absorption relative to water, scaled such that HU_{water} = 1000 HU
- Stoichiometric conversion method parameterises the response of the x-ray CT scanner
- For material with known chemical compositions, theoretical HU and stopping powers are then calculated
- Piecewise fit used as conversion curve

$$HU \propto \rho_e(K^{ph}\tilde{Z}^{3.62} + K^{coh}\hat{Z}^{1.86} + K^{KN})$$

$$\hat{Z}^{1.86} = \sum \lambda_i Z_i^{1.86}$$
 $\tilde{Z}^{3.62} = \sum \lambda_i Z^{3.62}$ **X-ray Absorption**

$$RSP =
ho_{e,rel} imes rac{\ln rac{2m_e c^2 eta^2}{(1-eta^2)I_{m,x}} - eta^2}{\ln rac{2m_e c^2 eta^2}{(1-eta^2)I_{w,x}} - eta^2}$$
 Stopping Power



Choice of materials